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ALI = acute lung injury; ARDS = acute respiratory distress syndrome; NF-κB = nuclear factor-κB.
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On page 24 of this issue of Critical Care, Meduri introduces
a new layer of complexity to our understanding of the
inflammatory response in acute respiratory distress syndrome
(ARDS). He postulates that cytokines secreted by the host
during ARDS may favor the growth of some strains of
bacteria and consequently explain the association between
exaggerated and protracted systemic inflammation and the
development of nosocomial infections [1]. Evidence for this
novel theory comes from in vitro studies evaluating the
extracellular and intracellular responses of clinically relevant
bacterial species to graded concentrations of pro-
inflammatory cytokines [2]. These studies demonstrate a U-
shaped bacterial growth response curve. Bacterial growth
was enhanced at both extremes of this curve, suggesting that
insufficient or dysregulated inflammation may play an active
role in stimulating bacterial growth and/or impairment of
bacterial clearance, with the subsequent development of
nosocomial infections. This new finding has important
implications for our understanding and management of
patients with ARDS.
Immune response and acute lung injury/ARDS
Over the past two decades, the recognition that neutrophils,
macrophages, and other components of the inflammatory
cascade participate in the generation and progression of
acute lung injury (ALI) and ARDS has resulted in the use of
anti-inflammatory agents as pharmacological probes to define
this syndrome. Furthermore, preclinical models of endotoxin-
induced sepsis demonstrated a survival benefit if pro-
inflammatory cytokines were neutralized [3], leading to a
number of studies in which this therapy was used in patients
with ARDS. The U-shaped bacterial growth curve may be a
partial explanation for the lack of efficacy of these trials as
decreasing cytokine activity may be beneficial, or may be
harmful, depending on the specific location on the dose
response curve.
For an effective host response to be mounted against
infection, the cellular components of the innate and acquired
immune system need bidirectional communication. Cytokines
are an important group of molecules through which this
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Abstract
The recognition that neutrophils, macrophages, and other components of the inflammatory cascade
participate in the generation and progression of acute lung injury/acute respiratory distress syndrome
has resulted in the use of anti-inflammatory agents in an attempt to attenuate this inflammatory
response and to prevent further progression of the acute lung injury. The recent finding that cytokines,
in part mediators of this ‘overwhelming’ inflammatory reaction, may also stimulate bacterial growth,
impair bacterial clearance, and promote the subsequent development of nosocomial infections may
have important implications to the management of the acute lung injury/acute respiratory distress
syndrome patient.
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process is initiated. The interaction between cytokines and
bacteria may be an important factor in the development of
organ injury and death from severe infections, although
numerous host and local factors, including inflammatory cells,
profoundly influence the role of a specific cytokine. It has
recently been proposed that patients with sepsis or a
systemic inflammatory response have an ‘immunoparalysis’
and are, in fact, immunosuppressed [4,5].
The use of growth factors or cytokines to augment the host
response to infection has been proposed in the critically ill. A
small preclinical trial with granulocyte colony stimulating
factor showed favorable mortality results in patients with
community acquired pneumonia and sepsis [6]. Although a
recent phase III trial did not detect a mortality difference
between the treatment and the placebo group in a post hoc
analysis, Nelson and colleagues [7] documented faster
radiological resolution of pneumonias, which was associated
with a decreased incidence of ARDS. Further evidence for
the role of augmentative cytokine therapy comes from clinical
data using interferon to upregulate HLA-DR expression and
consequently increase the lipopolysaccharide-induced tumor
necrosis factor-α responses ex vivo, and from improved
clinical outcome in eight out of nine septic patients [4].
In contrast, agents that block tumor necrosis factor-α,
interleukin-1, and endotoxin have been shown to attenuate
nuclear factor-κB (NF-κB) activation, inflammation, and organ
dysfunction. However, no agent has been shown to be
efficacious in human studies [8]. These studies, however, did
not look at the incidence of nosocomial pneumonia as an
outcome in patients with ARDS. From a biological standpoint, it
may be that blocking a single mediator, especially after the
initiating insult, is insufficient to inhibit NF-κB activation in
complex clinical conditions. This is primarily because of the
redundancy of proximal mediators with the potential to activate
NF-κB. Furthermore, none of these molecules appears to be
both a critical and essential pathway for activation of NF-κB [8].
From bench to bedside?
But can we extrapolate Meduri’s experiments to the bedside?
There are certainly a number of caveats. Firstly, these studies
were carried out in vitro. If we have learned anything from
clinical trials in sepsis/inflammation it is that the transfer of
information from the bench to the bedside can be fraught
with difficulty. The intricate relationship between innate and
adaptive response shapes patient outcome, and this is rarely
determined by a single factor. There are, in fact, many more
levels of complexity; with multiple cytokines and multiple U-
shaped curves that interact, it may be impossible to predict
whether a specific anti-cytokine therapy will benefit or harm a
given patient, especially as the cytokine profiles change
during the course of the disease.
Secondly, even if these concepts are correct in vivo, the
impact of nosocomial pneumonias on the mortality of patients
with ALI/ARDS in not entirely clear. Despite the fact that at
postmortem almost two-thirds of non-survivors have
histological evidence of pneumonia [9], Sutherland et al.
found that the incidence of nosocomial pneumonia in patients
with ARDS was only 15% (antibiotic use may have inhibited
bacterial growth in this study) [10]. Two prospective studies
in France reported a much higher incidence (55–60%)
[11,12]. In all three studies, however, the presence or
absence of ventilator-associated pneumonia had little or no
effect on mortality. In contrast, Headley et al. reported that
the rate of nosocomial infection per day of mechanical
ventilation was 1% in survivors and 8% in non-survivors [2].
The impact of nosocomial infections on mortality is hence not
entirely clear. 
Even if nosocomial infections do not directly determine
outcome in this population of patients, they may play a key
role in the loss of pulmonary compartmentalization of the
inflammatory response, and consequently the development
and progression of multi-organ dysfunction syndrome [13].
Data presented by Meduri suggest that bacterial growth and
impaired clearance is secondary to a dysregulated
inflammatory response [1] and is not the inciting event
leading to loss of pulmonary compartmentalization. Ranieri
and Slutsky, however, showed that an injurious ventilatory
strategy increases the level of serum inflammatory mediators
[14] and that this increase is related to an increased
incidence of organ dysfunction [15]. It has been postulated
that loss of pulmonary compartmentalization may explain
these findings. Whether this may be, in part, amplified by
concurrent nosocomial pulmonary infections and the U-
shaped dose response to cytokines is yet to be determined.
Moreover, treating cytokines in isolation of the underlying
pathophysiology may not alter important clinical outcomes.
Compelling evidence looking at different ventilatory strategies
in the management of patients with ARDS has demonstrated
that protective ventilatory strategies that attenuate the
pulmonary and systemic inflammatory responses, by
addressing the underlying pathophysiology of ventilator-
induced lung injury in patients with ARDS, improve outcome
[14–16]. Evidence from both animal and clinical studies
suggest that cyclic stretch induces changes in pro-
inflammatory and anti-inflammatory gene expression [14,17].
It consequently follows that mechanical forces may be
immunomodulatory. If this is the case, mechanical ventilation
primarily used in the treatment of respiratory failure and
responsible for ventilator-induced lung injury may now
become a therapeutic tool in the immunomodulatory
management of ventilated patients with ARDS.
Conclusion
This is an exciting time for intensivists involved in the care of
patients with ARDS/ALI. The rate-limiting step in developing
novel therapies for acute inflammatory diseases of the lung is
not delineating the molecular mechanisms of lung injury, butCritical Care    February 2002 Vol 6 No 1 dos Santos et al.
understanding how the pieces of the puzzle fit together. To
this end, Meduri has made a significant contribution to our
understanding of the mechanisms underlying nosocomial
infections in patients with ARDS. The challenge now is in the
generation of meaningful questions that will pave the way
towards novel strategies in the management of this patient
population. 
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